Navigation Links
CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

KING OF PRUSSIA, Pa., Dec. 22, 2016 /PRNewswire/ -- CSL Limited (ASX: CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability aspects important to its operations and stakeholders.

CSL Limited CEO and Managing Director Paul Perreault said the company continues to deliver on its promise to protect the health and wellbeing of people with rare and serious diseases.

"Ensuring the quality and safety of our products and therapies remains our most important sustainability asset," Perreault said. "It is critical to our value chain and most critical to the patients that depend on them for their quality of life and, in some cases, life itself. Adopting a holistic approach to the way we conduct business is central to the execution of our strategy."

Among other highlights, the 2015-2016 report details CSL's innovative manufacturing approach to enhancing the safety profile of immunoglobulin products. This leading edge innovation is just one example of how CSL strives to deliver on its promise to patients. In all cases, continuous improvement across CSL's material sustainability aspects supports the ability to sustainably deliver its objectives.

Spanning the reporting year July 2015 to June 30, 2016, CSL's economic, social and environmental achievements and challenges include:

  • Distribution of US$6 billion to local communities in the form of supplier payments, employee wages and benefits, shareholder returns and government taxes, including US$29.6 million in global community investment to patient, biomedical and local communities;
  • Global workforce of 17,021 employees, with women the majority at 55%; health and safety performance saw days lost and the medical treatment incident rate reduce by 12% and 20%, respectively, last year, with no fatalities across operations;
  • Research and Development investment of US$614 million with 48 clinical studies in operation across the pipeline; 24 product registrations or new indications for serious diseases in various markets, an increase of 71% over the previous year;
  • 281 Good Manufacturing Practice regulatory audits of CSL's manufacturing facilities and plasma collection centers with no impact on product marketing licenses – over the reporting period, CSL initiated three voluntary safety-related product recalls;
  • Across CSL's extensive plasma collection network, a donor survey response of 99.3% indicated a willingness to donate again.

About CSL

CSL (ASX:CSL) is a leading global biotherapeutics company with a dynamic portfolio of life-saving innovations, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses CSL Behring and Seqirus — conducts business in over 60 countries with more than 17,000 employees. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Media Contact
Chris Florentz
Office: 610-878-4316
Mobile: 484-238-8509

To view the original version on PR Newswire, visit:

Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression
2. Science Publication Highlights the Precision Medicine Approach of Geisinger Health System and the Regeneron Genetics Center
3. Science Publication Highlights the Precision Medicine Approach of the Regeneron Genetics Center and Geisinger Health System
4. Precision LTC Pharmacy Introduces Revolutionary Approach to Managing Multiple Medications
5. Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases
6. Philips is first to bring adaptive intelligence to radiology, delivering a new approach to how radiologists see, seek and share patient information
7. Best of Breed or Single Vendor Strategy in Radiology Imaging? Sectra Rated #1 in Customer Satisfaction Regardless of Approach
8. New Review of Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy
9. Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinsons Clinical Study
10. Frost & Sullivan Commends Philips Results-driven Approach to Creating Customer Value
11. Study Examines Current Approaches to Creating a Strategic Thought Leader Management System for Pharmaceutical Companies
Post Your Comments:
(Date:9/12/2019)... ... September 12, 2019 , ... ... , revenue cycle management services, integrated practice management, and patient engagement solutions, ... Sponsor at National User Conference (NUCON) 2019 . The annual conference ...
(Date:9/11/2019)... ... September 12, 2019 , ... ... Best Practices, An FDAnews Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, ... (DSCSA) implementation requirements? Is the company clear on nuances of the guidelines regulating ...
(Date:9/11/2019)... ... September 11, 2019 , ... Radiology… gastroenterology… ophthalmology… pathology… , ... evaluate medical images. In fact, image analysis software represents one of the fastest-growing ... to AI-based image analysis, one will be left behind. , As both a ...
Breaking Medicine Technology:
(Date:9/17/2019)... SARASOTA, Fla. (PRWEB) , ... September 17, 2019 ... ... plans and Dental Service Organizations (DSOs) has earned Michael Cole, Vice President of ... presented today by the National Association of Dental Plans (NADP) at their annual ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... join the largest accountable care organization (ACO) in the country, the company announced ... groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity is ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon ... , with the goal of providing resources to assist researchers and encourage pharmaceutical ... progressive disease causing abnormal iron deposits in the brain. , BPAN Warriors ...
(Date:9/14/2019)... Okla. (PRWEB) , ... September 14, 2019 , ... ... cannabis industry, has time and again tried to bring the most relevant and important ... ray of hope on an increasingly large number of people across the world suffering ...
(Date:9/11/2019)... ... September 11, 2019 , ... Global Education Group (Global), ... (CME) provider, is the official accreditor for PAINWeek, the largest US pain conference ... topics, as it has done for the past ten years. In addition, the ...
Breaking Medicine News(10 mins):